Global Poxviridae Infections Drug Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Poxviridae Infections Drug

• 1.1 Definition of Poxviridae Infections Drug
• 1.2 Poxviridae Infections Drug Segment by Type
  • 1.2.1 Global Poxviridae Infections Drug Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 CJ-40011
  • 1.2.3 24a
  • 1.2.4 BA-368
  • 1.2.5 Others
• 1.3 Poxviridae Infections Drug Segment by Applications
  • 1.3.1 Global Poxviridae Infections Drug Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Others
• 1.4 Global Poxviridae Infections Drug Overall Market
  • 1.4.1 Global Poxviridae Infections Drug Revenue (2014-2025)
  • 1.4.2 Global Poxviridae Infections Drug Production (2014-2025)
  • 1.4.3 North America Poxviridae Infections Drug Status and Prospect (2014-2025)
  • 1.4.4 Europe Poxviridae Infections Drug Status and Prospect (2014-2025)
  • 1.4.5 China Poxviridae Infections Drug Status and Prospect (2014-2025)
  • 1.4.6 Japan Poxviridae Infections Drug Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Poxviridae Infections Drug Status and Prospect (2014-2025)
  • 1.4.8 India Poxviridae Infections Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Poxviridae Infections Drug
• 2.3 Manufacturing Process Analysis of Poxviridae Infections Drug
• 2.4 Industry Chain Structure of Poxviridae Infections Drug

3 Development and Manufacturing Plants Analysis of Poxviridae Infections Drug

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Poxviridae Infections Drug Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Poxviridae Infections Drug
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Poxviridae Infections Drug Production and Capacity Analysis
• 4.2 Poxviridae Infections Drug Revenue Analysis
• 4.3 Poxviridae Infections Drug Price Analysis
• 4.4 Market Concentration Degree

5 Poxviridae Infections Drug Regional Market Analysis

• 5.1 Poxviridae Infections Drug Production by Regions
  • 5.1.1 Global Poxviridae Infections Drug Production by Regions
  • 5.1.2 Global Poxviridae Infections Drug Revenue by Regions
• 5.2 Poxviridae Infections Drug Consumption by Regions
• 5.3 North America Poxviridae Infections Drug Market Analysis
  • 5.3.1 North America Poxviridae Infections Drug Production
  • 5.3.2 North America Poxviridae Infections Drug Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Poxviridae Infections Drug Import and Export
• 5.4 Europe Poxviridae Infections Drug Market Analysis
  • 5.4.1 Europe Poxviridae Infections Drug Production
  • 5.4.2 Europe Poxviridae Infections Drug Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Poxviridae Infections Drug Import and Export
• 5.5 China Poxviridae Infections Drug Market Analysis
  • 5.5.1 China Poxviridae Infections Drug Production
  • 5.5.2 China Poxviridae Infections Drug Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Poxviridae Infections Drug Import and Export
• 5.6 Japan Poxviridae Infections Drug Market Analysis
  • 5.6.1 Japan Poxviridae Infections Drug Production
  • 5.6.2 Japan Poxviridae Infections Drug Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Poxviridae Infections Drug Import and Export
• 5.7 Southeast Asia Poxviridae Infections Drug Market Analysis
  • 5.7.1 Southeast Asia Poxviridae Infections Drug Production
  • 5.7.2 Southeast Asia Poxviridae Infections Drug Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Poxviridae Infections Drug Import and Export
• 5.8 India Poxviridae Infections Drug Market Analysis
  • 5.8.1 India Poxviridae Infections Drug Production
  • 5.8.2 India Poxviridae Infections Drug Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Poxviridae Infections Drug Import and Export

6 Poxviridae Infections Drug Segment Market Analysis (by Type)

• 6.1 Global Poxviridae Infections Drug Production by Type
• 6.2 Global Poxviridae Infections Drug Revenue by Type
• 6.3 Poxviridae Infections Drug Price by Type

7 Poxviridae Infections Drug Segment Market Analysis (by Application)

• 7.1 Global Poxviridae Infections Drug Consumption by Application
• 7.2 Global Poxviridae Infections Drug Consumption Market Share by Application (2014-2019)

8 Poxviridae Infections Drug Major Manufacturers Analysis

• 8.1 Bavarian Nordic A/S
  • 8.1.1 Bavarian Nordic A/S Poxviridae Infections Drug Production Sites and Area Served
  • 8.1.2 Bavarian Nordic A/S Product Introduction, Application and Specification
  • 8.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 BioFactura, Inc.
  • 8.2.1 BioFactura, Inc. Poxviridae Infections Drug Production Sites and Area Served
  • 8.2.2 BioFactura, Inc. Product Introduction, Application and Specification
  • 8.2.3 BioFactura, Inc. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 CEL-SCI Corporation
  • 8.3.1 CEL-SCI Corporation Poxviridae Infections Drug Production Sites and Area Served
  • 8.3.2 CEL-SCI Corporation Product Introduction, Application and Specification
  • 8.3.3 CEL-SCI Corporation Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Chimerix, Inc.
  • 8.4.1 Chimerix, Inc. Poxviridae Infections Drug Production Sites and Area Served
  • 8.4.2 Chimerix, Inc. Product Introduction, Application and Specification
  • 8.4.3 Chimerix, Inc. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 China Biologic Products, Inc.
  • 8.5.1 China Biologic Products, Inc. Poxviridae Infections Drug Production Sites and Area Served
  • 8.5.2 China Biologic Products, Inc. Product Introduction, Application and Specification
  • 8.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 CJ HealthCare Corp.
  • 8.6.1 CJ HealthCare Corp. Poxviridae Infections Drug Production Sites and Area Served
  • 8.6.2 CJ HealthCare Corp. Product Introduction, Application and Specification
  • 8.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 EpiVax, Inc.
  • 8.7.1 EpiVax, Inc. Poxviridae Infections Drug Production Sites and Area Served
  • 8.7.2 EpiVax, Inc. Product Introduction, Application and Specification
  • 8.7.3 EpiVax, Inc. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 N & N Pharmaceuticals Inc.
  • 8.8.1 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Production Sites and Area Served
  • 8.8.2 N & N Pharmaceuticals Inc. Product Introduction, Application and Specification
  • 8.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 SIGA Technologies, Inc.
  • 8.9.1 SIGA Technologies, Inc. Poxviridae Infections Drug Production Sites and Area Served
  • 8.9.2 SIGA Technologies, Inc. Product Introduction, Application and Specification
  • 8.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Takeda Pharmaceutical Company Limited
  • 8.10.1 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Production Sites and Area Served
  • 8.10.2 Takeda Pharmaceutical Company Limited Product Introduction, Application and Specification
  • 8.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Tonix Pharmaceuticals Holding Corp.
• 8.12 Verrica Pharmaceuticals Inc.

9 Development Trend of Analysis of Poxviridae Infections Drug Market

• 9.1 Global Poxviridae Infections Drug Market Trend Analysis
  • 9.1.1 Global Poxviridae Infections Drug Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Poxviridae Infections Drug Regional Market Trend
  • 9.2.1 North America Poxviridae Infections Drug Forecast 2019-2025
  • 9.2.2 Europe Poxviridae Infections Drug Forecast 2019-2025
  • 9.2.3 China Poxviridae Infections Drug Forecast 2019-2025
  • 9.2.4 Japan Poxviridae Infections Drug Forecast 2019-2025
  • 9.2.5 Southeast Asia Poxviridae Infections Drug Forecast 2019-2025
  • 9.2.6 India Poxviridae Infections Drug Forecast 2019-2025
• 9.3 Poxviridae Infections Drug Market Trend (Product Type)
• 9.4 Poxviridae Infections Drug Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Poxviridae Infections Drug Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List